PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 637: CyTOF analysis of heterogeneity between Ewing sarcoma cell lines in vitro and in vivo.

View Full Paper
PHPiper HarrellAtrium Health Wake Forest BaptistLGLily GolzarAtrium Health Wake Forest BaptistKWKenzie WellsAtrium Health Wake Forest Baptist

Key Points

  • This study aims to assess the heterogeneity of EWS:FLI1 fusion and cancer stem cells across Ewing sarcoma cell lines using CyTOF analysis.
  • Used CyTOF to analyze Ewing sarcoma cell lines A673, TC71, RDES, and SL00015 in vitro and in vivo.
  • Cells were stained for CyTOF analysis after being seeded at equal numbers.
  • In vivo tumors were generated in Nude mice, harvested, and dissociated for analysis.
  • OMIQ software facilitated data analysis, including phenograph clustering and UMAP visualization.
  • Cell lines exhibited varying morphologies and growth characteristics both in vitro and in vivo.
  • In vivo cells showed a higher percentage of EWS:FLI1low populations compared to their in vitro counterparts.
  • Cancer stem cell populations varied, typically being higher in vitro than in vivo.
  • Immune cell infiltration levels differed with RDES tumors displaying the most significant immune presence.

Abstract

Abstract Introduction: Ewing sarcoma (ES) is the second most common bone cancer in children and is known to be driven by an oncogenic fusion, most commonly EWS:FLI1. Recent work has identified that ES tumors are heterogenous and there are populations of cells within tumors with varying levels of the EWS:FLI1 fusion. These populations have differences in morphology, proliferation, drug sensitivities, and invasiveness. Further, it is known that cancer stem cell populations are also found within ES tumors and these cells also have differences in morphology and drug sensitivity. The purpose of this study was to use CyTOF to assess differences in EWS:FLI1 fusion and cancer stem cell heterogeneity and immune infiltration between various ES cell lines in vitro and in vivo. Methods: In vitro, A673, TC71, RDES, and SL00015 cells were seeded separately at equal numbers and stained for CyTOF the following day. In vivo, A673, RDES, or SL00015 cells were injected subcutaneously into Nude mice. Once tumors reached 1500-2000mm3, they were harvested and dissociated for CyTOF analysis. The CyTOF panel used was designed to assess EWS:FLI1 fusion heterogeneity, the cancer stem cell population, and immune cell infiltration. OMIQ was used for data analysis which included phenograph clustering with UMAP visualization, heatmap of expression patterns, and changes in tumor and immune cell populations. Results: In vitro, each of the 4 cell lines have varying morphologies and their growth ranges from adherent to clusters of cells in suspension. Phenograph clustering revealed different expression patterns among the cell lines. Interestingly, the expression patterns of different cell lines grown in vivo clustered together more than the in vivo grown cells did with their in vitro counterpart. Overall, the cells grown in vivo had a higher percentage of the EWS:FLI1low population compared to the respective cell line grown in vitro. The amount of cancer stem cells varied among cell lines and sample types, though the percentage was generally higher in the in vitro samples compared to in vivo. Further, immune infiltration also varied across tumors formed from different cell lines with the RDES tumors having the most overall infiltration. Conclusions: The CyTOF panel used in this study can identify distinct expression patterns among cell lines and sample types. The differences in expression patterns identified between a cell line grown in vitro or in vivo could be an important consideration in drug efficacy or mechanism studies in the context of Ewing sarcoma. Citation Format: Piper Harrell, Lily Golzar, Kenzie Wells, Poornima Gourabathini, Kimberly Q. McKinney, Erin M. Trovillion, Javier Oesterheld, Kaitlyn H. Smith. CyTOF analysis of heterogeneity between Ewing sarcoma cell lines in vitro and in vivo abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 637.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Harrell et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdf7a79560c99a0a4586https://doi.org/10.1158/1538-7445.am2026-637
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 635: Defining the intertumoral and intratumoral transcriptional heterogeneity of EWS::FLI1 in Ewing sarcoma.2026
  2. 2Abstract 6195: Spatial transcriptomics analysis reveals tumor cell plasticity and diverse tumor microenvironments in Ewing sarcoma2026 · 1 citations
  3. 3Abstract 5695: CyTOF analysis of targeted therapy in addition to standard of care against Ewing sarcoma tumor subpopulations2026
  4. 4Abstract 3950: Dedifferentiation unveils origin of Ewing sarcoma2024
  5. 5Abstract A015: Targetable gene dependencies in Ewing sarcoma subtypes2025